Marquis Who's Who Millennium Magazine

Marquis Millennium Magazine

B oard certified in internal medicine and medical oncology, Dr. Paul F. Engstrom has over 50 years of experience diagnosing and treating blood diseases and cancers. Dr. Engstrom became interested in medicine as a career because his father was a family physician in rural Minnesota with a clinic in the front of their home. When he was in medical school, the school had a very strong program in oncology. He enjoyed the work and saw it as a burgeoning field with new advances in DNA. To prepare for his career, he earned a Bachelor of Science from St. Olaf College in 1958 and an MD from the University of Minnesota in 1962. After earning his credentials, he honed his skills as an intern and resident in internal medicine at the University of Minnesota Hospital from 1963 to 1967. He went on to become chief of

Paul F. Engstrom, MD Hematology/Oncology Advisor to the President, Section Chief, Professor Fox Chase Cancer Center Philadelphia, PA

the hematology and oncology section of Tripler Army Medical Center in Honolulu, Hawaii for three years before settling in Philadelphia. In Philadelphia, he was an attending physician in medicine at American Oncologic Hospital, as well as chairman of the department of medicine and vice president of population science at Fox Chase Cancer Center, a position he has held since 1984. Dr. Engstrom shared his knowledge and expertise of the field as an editor and author of “Advances in Cancer Control” and “Cancer Epidemiology Biomarkers and Prevention” and has contributed chapters to books. Alongside his medical career, he delved into education as a professor at the Temple University School of Medicine from 1987 to 1995. Dr. Engstrom remains abreast of the field as a fellow of the American College of Physicians and a member of the American Medical Association, the American Society of Clinical Oncology, the American Federation for Clinical Research, the American Association for Cancer Education, and the American Society of Preventive Oncology.

125